BRAF and neoplasm: Here, by studying a panel of BRAFV600E melanoma cell lines with acquired resistance to BRAFi and plasma and tumor samples from vemurafenib-treated melanoma patients, we show that the CCL2 production by melanoma cells is involved in the resistance to BRAF inhibition and that its inhibition may restore drug sensitivity.